This month PRECISIONheor would like to highlight the work and expertise of Senior Director Ivar Jensen. Ivar specializes in the development of health economic models to support access, reimbursement negotiations and payer discussions.

He has supported clients with developing credible evidence-based models across the full spectrum of health economic models including cost-consequence, budget impact, cost-effective, and other health economic models and calculators.

Some of Ivar’s recent impactful publications that demonstrate his expertise in cost-consequence modeling include:

• Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective
• Cost–consequence analysis of 18F-fluciclovine for the staging of recurrent prostate cancer.

He also contributed to three noteworthy publications utilizing budget impact models:

• Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes
• Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives (tandfonline.com)
• The health economic impact of varying levels of adherence to colorectal screening on providers and payers (tandfonline.com)

Lastly, below are two additional publications featuring his work with cost-effective models:

• Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients
• An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)

To speak with Ivar directly, contact him at ivar.jensen@precisionvh.com.